The Reality of Monitoring in Quebec, Canada
In Quebec, the reality of clinical monitoring—the oversight of clinical trials to ensure data integrity, patient safety, and regulatory compliance—exists at a unique crossroad.
It balances the globalized, English-language enabled pharmaceutical industry with Quebec’s provincial language barriers and laws, specifically Bill 96 (the 2022 overhaul of the Charter of the French Language).
The operational reality for Clinical Research Associates (CRAs) and monitoring teams in the province comes down to a few key areas.
The Institutional Dichotomy (Global vs. Local)
Clinical trials are inherently global. Because phase III trials span dozens of countries, the foundational study infrastructure is almost exclusively managed in English to maintain cross-border uniformity. However, once that trial touches a hospital or clinic in Quebec, the language landscape splits:
The Global Facing Side (English): The research protocol, Investigator’s Brochure (IB), sponsor Standard Operating Procedures (SOPs), electronic Case Report Forms (eCRFs), and standard monitoring reports are almost universally kept in English so global data managers and regulators (like the FDA or EMA) can parse them.
The Site-Facing Side (French): Source documentation—such as patient medical charts, hospital logs, nursing notes, and local lab reports—is written in French at the vast majority of Quebec sites (especially outside the immediate Montreal area).